Disability

Veru to Participate in the BTIG Virtual Biotechnology Conference

MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

NAVIGANTIS Secures $12 Million to Advance the Development of its VASCO Robotic Platform

MIAMI, July 25, 2024 /PRNewswire/ -- NAVIGANTIS Inc. announced today that it has closed a $12 million Series A financing led…

2 years ago

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and…

2 years ago

30 Days to Greater Impact: Voiceitt’s Free Trial Empowers Therapists to Help Clients with Non-Standard Speech

Speech Recognition Startup Announces New Program for Speech Pathologists and Other Therapy Professionals to Expand the Impact of its Inclusive Voice AI…

2 years ago

Policymakers should recognise #SelfCareIsHealthcare in campaign bid to address global health challenges

Self-care is healthcare Self-care is healthcare Self-care describes the role of individuals in preventing disease, promoting and maintaining their mental…

2 years ago

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome

U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel…

2 years ago

Elucid Names Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis softwareBOSTON--(BUSINESS WIRE)--Elucid, a…

2 years ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had…

2 years ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had…

2 years ago

Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs…

2 years ago